{"id":"https://openalex.org/W33978685","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.1081","title":"N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy","display_name":"N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy","publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W33978685","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.1081","mag":"33978685"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.26.15_suppl.1081","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.1081","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.1081","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078619764","display_name":"Timothy J. Hobday","orcid":"https://orcid.org/0000-0002-9877-3372","observed_orcids":["https://orcid.org/0000-0002-9877-3372"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. J. Hobday","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112869121","display_name":"Phillip J. Stella","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. J. Stella","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109263888","display_name":"Tom R. Fitch","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. R. Fitch","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049992163","display_name":"Anthony John Jaslowski","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Jaslowski","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044733637","display_name":"Betsy R LaPlant","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. LaPlant","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066722006","display_name":"Matthew M. Ames","orcid":"https://orcid.org/0000-0003-3652-209X","observed_orcids":["https://orcid.org/0000-0003-3652-209X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. M. Ames","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008665323","display_name":"Matthew Philip Goetz","orcid":"https://orcid.org/0000-0002-4383-270X","observed_orcids":["https://orcid.org/0000-0002-4383-270X","https://orcid.org/0000-0003-3588-024X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. P. Goetz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5065306642","display_name":"Edith A. Perez","orcid":"https://orcid.org/0000-0002-5037-6677","observed_orcids":["https://orcid.org/0000-0002-5037-6677","https://orcid.org/0000-0001-7009-7467"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. A. Perez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":17,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"15_suppl","first_page":"1081","last_page":"1081"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.7113999724388123,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.7113999724388123,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.18320000171661377,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.05079999938607216,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":0.9290000200271606},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9959999918937683},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.8529999852180481},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.503000020980835},{"id":"https://openalex.org/keywords/anthracycline-based-chemotherapy","display_name":"anthracycline chemotherapy","score":0.746999979019165},{"id":"https://openalex.org/keywords/taxane-based-chemotherapy","display_name":"taxane-based chemotherapy","score":0.984000027179718},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6890000104904175},{"id":"https://openalex.org/keywords/ugt1a1-polymorphism","display_name":"UGT1A1 polymorphism","score":0.7850000262260437},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.39399999380111694},{"id":"https://openalex.org/keywords/early-trial-termination","display_name":"early trial termination","score":0.5299999713897705},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.6930000185966492},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.7540000081062317},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.527999997138977},{"id":"https://openalex.org/keywords/anti-egfr-therapy","display_name":"anti-EGFR therapy","score":0.36800000071525574}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9223822355270386},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.8007216453552246},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7278857231140137},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.7124854326248169},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.686179518699646},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6141002178192139},{"id":"https://openalex.org/C2776802502","wikidata":"https://www.wikidata.org/wiki/Q417589","display_name":"Anthracycline","level":4,"score":0.5706687569618225},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5554065108299255},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5509377121925354},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.47410279512405396},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.472406804561615},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.47217196226119995},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43080225586891174},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3762074410915375},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.2885318994522095},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.20699045062065125}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2008.26.15_suppl.1081","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.1081","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.1081","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1631575083","https://openalex.org/W2594586947","https://openalex.org/W2026240145","https://openalex.org/W2794380220","https://openalex.org/W2282712090","https://openalex.org/W2260692731","https://openalex.org/W2243164797","https://openalex.org/W3215791838","https://openalex.org/W2157717971","https://openalex.org/W1923056904"],"abstract_inverted_index":{"1081":[0],"Background:":[1],"Irinotecan":[2,321],"has":[3,324],"a":[4,43,130,163,257,270,287,304,335],"23%":[5],"response":[6,230,360],"rate":[7,197,231],"(RR)":[8],"in":[9,29,32,53,248,277,327,339],"patients":[10,278,343],"(pts)":[11],"with":[12,34,48,56,67,129,179,263,279,286,303,344],"previously":[13],"treated":[14],"metastatic":[15],"breast":[16],"cancer":[17,55],"(MBC)":[18],"(Perez,":[19],"JCO":[20],"2004).":[21],"Epidermal":[22],"growth":[23],"factor":[24],"receptor":[25],"(EGFR)":[26],"is":[27,42,331],"overexpressed":[28],"MBC,":[30,68],"especially":[31],"those":[33],"ER-/PR-":[35],"and":[36,71,90,182,194,215,232,322,342],"HER2-negative":[37],"tumors":[38],"(triple-negative,":[39],"[TNeg]).":[40],"Cetuximab":[41],"monoclonal":[44],"antibody":[45],"against":[46],"EGFR":[47,362],"additive":[49],"activity":[50,326],"to":[51,127,290,361],"irinotecan":[52,91],"colorectal":[54],"acceptable":[57],"toxicity.":[58],"Methods:":[59],"This":[60],"one-stage":[61],"phase":[62],"II":[63],"study":[64,236],"enrolled":[65,124],"pts":[66,123,221,283,300,341],"measurable":[69],"disease,":[70,141],"prior":[72,157],"anthracycline":[73],"and/or":[74,145],"taxane":[75],"therapy.":[76],"Pts":[77,161],"received":[78,162],"cetuximab":[79,323],"400":[80],"mg/m2":[81,88,93],"day":[82],"1":[83,85,180,183],"cycle":[84],"then":[86],"250":[87],"weekly":[89],"80":[92],"days":[94],"1,":[95],"8":[96],"of":[97,133,165,170,272,292,308],"each":[98],"21-day":[99],"cycle.":[100],"Primary":[101],"endpoint":[102],"was":[103,112,118,174,210,334],"confirmed":[104],"RR":[105,173,193,199],"by":[106],"RECIST":[107],"criteria.":[108],"Planned":[109],"sample":[110],"size":[111],"36.":[113],"Genotyping":[114],"for":[115,159,190,205,359],"UGT1A1":[116,315],"polymorphisms":[117],"performed.":[119],"Results:":[120],"19":[121],"eligible":[122],"from":[125],"2/06":[126],"9/06":[128],"median":[131,164,288,305],"age":[132],"49":[134],"yrs":[135],"(range:":[136,168],"28\u201376),":[137],"74%":[138],"had":[139,156,187,256,269],"visceral":[140],"32%":[142],"were":[143,149,153],"ER":[144],"PR":[146,181],"positive,":[147,151],"11%":[148,175],"HER2":[150],"58%":[152],"TNeg.":[154],"79%":[155],"chemotherapy":[158],"MBC.":[160],"2":[166,226,266,347],"cycles":[167],"1\u201311)":[169],"treatment.":[171],"Confirmed":[172],"(95%":[176,295,311],"CI:":[177,296,312],"1\u201333%),":[178],"CR.":[184],"One":[185],"pt":[186,352],"stable":[188,201],"disease":[189],"11":[191],"cycles.":[192,227],"clinical":[195],"benefit":[196],"(CBR:":[198],"+":[200],">":[202,258],"6":[203],"months)":[204],"Tneg":[206,209,340],"vs":[207,212,217,275],"non-":[208],"18%":[211],"0%":[213,218,276],"(p=0.49)":[214],"27%":[216],"(p=0.23).":[219],"12":[220],"progressed":[222,285],"on":[223],"therapy":[224],"within":[225],"With":[228],"low":[229],"rapid":[233],"progression,":[234],"the":[235],"closed":[237],"early.":[238],"NCI":[239,366],"CTC":[240],"version":[241],"3":[242],"grade":[243,264,280,345],"3\u20134":[244],"adverse":[245],"events":[246],"occurred":[247],"10":[249],"pts;":[250],"only":[251],"dermatologic":[252],"toxicity":[253],"(derm":[254],"tox)":[255],"5%":[259],"incidence":[260],"(26%).":[261],"Patients":[262],"\u2265":[265,346],"derm":[267,348],"tox":[268],"CBR":[271,338],"21%":[273],"(3/14)":[274],"0\u20131.":[281],"18":[282],"have":[284,301],"time":[289],"progression":[291],"1.4":[293],"mos":[294,310],"1.1\u20132.2":[297],"mos).":[298,314],"15":[299],"died":[302],"overall":[306],"survival":[307],"9.4":[309],"3.3\u201316.1":[313],"results":[316],"will":[317],"be":[318],"presented.":[319],"Conclusions:":[320],"minimal":[325],"this":[328],"population.":[329],"Tolerability":[330],"acceptable.":[332],"There":[333],"numerically":[336],"higher":[337],"tox,":[349],"but":[350],"small":[351],"numbers":[353],"limit":[354],"conclusions.":[355],"Better":[356],"predictive":[357],"factors":[358],"inhibition":[363],"are":[364],"needed.":[365],"CA-25224,":[367],"CA-63848,":[368],"CA-37404,":[369],"CA-":[370],"60276,":[371],"Bristol-Myers":[372,393],"Squibb,":[373],"Imclone":[374],"systems":[375],"Author":[376],"Disclosure":[377],"Employment":[378],"or":[379,382],"Leadership":[380],"Consultant":[381],"Advisory":[383],"Role":[384],"Stock":[385],"Ownership":[386],"Honoraria":[387],"Research":[388],"Expert":[389],"Testimony":[390],"Other":[391],"Remuneration":[392],"Squibb":[394]},"counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-06-24T00:00:00"}